Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 25, 2003. The report primarily details corporate governance matters, specifically changes in directors' interests in ordinary shares and American Depositary Shares (ADS), as well as a share repurchase transaction.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data points disclosed relate to share transactions:
- Share Repurchase Price: 1,146.99 pence per share.
- Trust Share Sale Price: 11.71 pounds per share.
- US Retirement Plan Average Price: $36.43 per share.
Material Changes and Transactions
The following material events were reported for the period:
- Share Repurchase: On February 24, 2003, the company purchased 870,000 Ordinary 25 pence shares for cancellation at 1,146.99 pence per share, utilizing authority granted at the May 20, 2002 Annual General Meeting.
- Director's Award Deferral: Dr. J-P Garnier elected to defer receipt of a final award of 36,985 American Depositary Shares until retirement following vesting confirmation.
- Employee Benefit Trust Activity: The SmithKline Beecham Employee Benefit Trust transferred 3,410 Ordinary shares to participants of the 1991 Share Option Plan and sold 1,093 ordinary shares on February 18, 2003.
- US Retirement Plan Movement: The GlaxoSmithKline US Retirement Savings Plan increased its holdings of Ordinary Share ADRs from 18,265,581 to 18,463,757 on February 20, 2003.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a notification of director interests and share transactions.
Key Facts for Investor Verification
- Verify the total number of shares repurchased for cancellation in the current fiscal year to assess capital return strategy.
- Confirm the impact of the 870,000 share repurchase on the company's total outstanding share count.
- Review the full terms of the SmithKline Beecham 1991 Share Option Plan and the US Retirement Savings Plan to understand the scope of director interests.
- Check subsequent filings for the final vesting and settlement details of Dr. Garnier's deferred award.